Consuming only this amount of cinnamon may interfere with blood pressure medication
A recent study reveals that cinnamon, a popular spice, can interfere with prescription medications due to compounds like coumarin and cinnamaldehyde. Dr. Clint Steele warns that consuming a teaspoon or more daily may disrupt blood pressure and blood thinner medications. Researchers advise caution, especially for those with chronic conditions, suggesting consultation with doctors before using cinnamon as a supplement.
Cinnamon
is one of the oldest and most commonly used
spice
s in the world. From baked goods to beverages, this spice is used in many foods. However, a new study found that cinnamon interacts with prescription medications.
A new study from the National Center for Natural Products Research found that a compound in cinnamon could interfere with some prescription medications.
The study is published in
Food Chemistry: Molecular Sciences
.
Dr. Clint Steele, a brain and nervous system specialist with over 300K followers on Instagram, has now shared about how that cinnamon sprinkle could deliver undesirable results. In a video shared on Instagram, Dr. Steele points out that consuming as little as one teaspoon or more of cinnamon daily could disrupt the effects of blood pressure medications and blood thinners due to a compound called coumarin, which acts as a natural blood thinner.
This overconsumption may amplify the medications' effects, potentially leading to complications. However, Steele emphasizes that smaller doses of cinnamon can still offer health benefits. 'One eighth of a teaspoon actually helps to reverse cognitive decline. You can see my other videos regarding that research,' he said in the video. Steele urges those on blood pressure medications or blood thinners to consult their doctors before adding cinnamon to their diets.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Tap Into Real-Time Signals Designed to Support Your Trading Decisions
Trader Headline
Learn More
Undo
'I'm no means telling you to replace your medication with cinnamon,' he clarifies, 'I want you to understand the facts and talk to your doctor.'
Meanwhile, researchers of the recent study found that cinnamaldehyde, a primary component of cinnamon, activates receptors that control the metabolic clearance of the medication from the body. This is why, when consumed in large amounts, cinnamon could reduce the effects of drugs.
'Health concerns could arise if excessive amounts of supplements are consumed without the knowledge of a health care provider or prescriber of the medications.
Overconsumption of supplements could lead to a rapid clearance of the prescription medicine from the body, and that could result in making the medicine less effective,' Shabana Khan, the principal scientist of the centre, said in a statement.
Study Biotech & Health Tech Abroad: Top Courses at Harvard, Stanford
'In contrast, true cinnamon from Sri Lanka carries a lower risk due to its reduced coumarin content.
Coumarin's anticoagulant properties can be hazardous for individuals on blood thinners,' Amar Chittiboyina, the center's associate director, noted.
What should you do?
The new study confirms that
cinnamon
can interact with certain prescribed medications. But does that mean you should stop having a cinnamon latte or indulging in the succulent fajitas? No, a little sprinkle of cinnamon won't hurt, but the researchers urge that you take the advice of your doctor, especially if you are interested in using cinnamon as a dietary supplement. They also ask people with chronic diseases like hypertension, diabetes, cancer, arthritis, asthma, obesity, HIV, AIDS, or depression to be cautious when using cinnamon or any other supplements.
Get the latest lifestyle updates on Times of India, along with
Mother's Day wishes
,
messages
, and
quotes
!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Census to identify persons with disabilities launched in Coimbatore district
Coimbatore: TN RIGHTS project, under the department of welfare for differently-abled persons, has launched a social registry enrolment (SRE) census to identify persons with disabilities (PwD) in Coimbatore. Under the initiative, data of persons with disabilities will be collected across all blocks, town panchayats, municipalities, and within the Coimbatore corporation limits in the district. Workers will visit every household to identify PwDs. P Sundareswaran, project officer for TN RIGHTS in Coimbatore district, said the survey began on June 2 and will continue till the end of August. "A total of 180 community rehabilitation workers are involved in the survey. They will visit every household and enter the details into a mobile application. During the survey, the workers will collect information, including socio-economic status, the kind of support the individual currently receives, any additional support is needed, and their expectations. After the survey, the data will be shared with the state govt," he said. "We have categorized disabilities into 21 types. The national average of persons with disabilities in the total population is 2.27%, whereas in Tamil Nadu, it is estimated to be 1.77%. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trading CFD dengan Teknologi dan Kecepatan Lebih Baik IC Markets Mendaftar Undo However, we suspect the actual percentage could be higher," he added. District differently-abled welfare officer Chandramohan said that after the eradication of polio, there is a growing number of people with intellectual disabilities, mental illness, and autism. "We don't have a comprehensive data on persons with intellectual disabilities. That's why we are now focusing on data collection. Without accurate data, we cannot plan appropriate schemes or provide proper rehabilitation services," he said. "The main aim of this survey is to determine how many people require rehabilitation. For those with mild disabilities, if proper rehabilitation is provided, there is an 80% chance of complete recovery. Without timely intervention, the condition can progress from mild to moderate and eventually become severe," he added.
Time of India
an hour ago
- Time of India
Bupa weighs foray into private hospitals market in India
British health insurance major Bupa is looking to enter the fast-growing private hospital and healthcare market in India, currently dominated by players like Max Healthcare, Apollo Hospitals, Fortis, Narayana Health, and Medanta, as the company grows its engagement beyond the traditional insurance business (Niva Bupa), global CEO Inaki Ereno told TOI in an interview. Excerpts: How do you assess the Indian health insurance market in India? The Indian health insurance market is the most attractive and best in the world. It's still under-penetrated, and we believe there will be many more people requiring private medical insurance. We need more beds, more hospitals, more clinics, and more insurance here... In terms of our own growth, it's been 35% over the last three years. We're clearly seeing a massive opportunity. In markets like Europe, UK, Australia , Latin America, you have a Bupa Payvider programme where you provide not just insurance and easy claims processing, but also a network of healthcare providers. These include dental and mental health clinics, and hospitals. Any plans to start hospitals and such other services in India? With Payvider, we are not just insurers but also providers. Of the claims that our patients go through, we always want around 25% in a place called Bupa - in a Bupa clinic, in a Bupa hospital, in a Bupa digital place. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Buy Brass Idols - Handmade Brass Statues for Home & Gifting Luxeartisanship Buy Now Undo This helps us to learn the cost of things, and also allows us to personalise the service. It is too soon to talk about India. I cannot commit yet on the dates but, yes, you can expect that Bupa will keep investing here... we do have a plan, a commitment to study the situation and be ambitious and come up with something big. We believe that 25% of the activity that we do should be run in a place like Bupa. Inflation in health costs is a concern for customers, which also sees policy costs go up. Your views? When it comes to the cost of claims, there is inflation across the world. This is why developing a private medical insurance market helps everybody. When you have more people into private medical insurance, that helps lower costs of claims. Normally, premiums go up with inflation. So, they will not reduce. Are we expecting a big increase in premiums? The answer is no. We expect premiums to go in line with the Consumer Price Index (CPI). Apart from metros and bigger cities, how do you see the opportunity in Tier 2 and Tier 3 towns and rural India? We are clearly targeting markets beyond the top 50-60 cities. We think there's a massive opportunity to get people into the fold of insurance. India is at a very nascent stage, and awareness is still low with respect to health insurance. India is a growing country, with lots of construction and other infrastructure activities happening. Do you think that dust, pollution, and long traffic snarls in congested cities create health hazards for people? The answer is yes, though no one can make a direct correlation in elements like these. But we are working with the Norman Foster Foundation to understand what is the impact that living in a particular city has on your health, including in Delhi. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
an hour ago
- Time of India
Are antibiotics losing battle against typhoid?
1 2 3 Ahmedabad: A recent study has raised alarm bells about the growing resistance of typhoid-causing bacteria to several antibiotics, in some cases up to 90%, potentially complicating treatment options for this common disease. This study by Gujarat Biotechnology Research Centre (GBRC) scientists, along with other organisations, is the latest among several studies in the past decade that flagged the rise of AMR typhoid in Gujarat and in India. Researchers studied isolated Salmonella Typhi or S Typhi, the bacteria responsible for typhoid fever, collected from Ahmedabad and Vadodara against 28 antibiotics used for treatment of typhoid and found several of them showing over 90% resistance. The group also pinpointed genes for third-generation antibiotics for some classes and suggested another class of antibiotics. Typhoid fever, caused by contaminated food or water or poor hygiene, is a common disease for Asia, Africa and Latin America and is marked by fever, fatigue, abdominal pain, rashes and in extreme cases, intestinal bleeding. Symptoms generally last for five to six days and doctors generally use antibiotics for treatment. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo In Ahmedabad city, monsoons often see 200-odd cases a month. The study, 'Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy' was recently published in the American Society for Microbiology journal Microbiology Spectrum. Its authors include SD Akshay, Heli Upadhyaya and 16 others from GBRC, MS University of Baroda, BJ Medical College, state govt's Commissionerate of Health, and Toprani Labs in Vadodara. 'Determining fluoroquinolones (FQs) and third-generation cephalosporin resistance underscores the urgent need for alternative therapeutic strategiesOur research revealed alarming resistance trends to key antibiotics, such as ceftriaxone, cotrimoxazole, amikacin, ampicillin, cefepime, cefixime, cefotaxime, ciprofloxacin, tetracycline, and gentamicin, limiting effective hospital treatment approaches,' the findings state. The researchers also highlighted the role of specific plasmids that carry resistance genes.'Our findings revealed that combination therapy with β-lactam antibiotics and β-lactam inhibitors (BLI) significantly improved the treatment efficacy against extensively drug resistant (XDR) S. Typhi, contributing to more favourable clinical results and reducing treatment failures,' read the findings, adding that this can effectively manage infections and avoid resistance development. Health experts in Ahmedabad say that the drug-resistant typhoid has been a reality for nearly a decade, in varied frequencies. Dr Urvesh Shah, professor and head of GCS Medical College's microbiology department, said that quinolone, the drug of choice a decade ago, is now getting resistant in more than 50% cases. "While third-generation cephalosporin are a drug of choice, we now get scattered cases of its resistance, which is alarming. While azithromycin retains its sensitivity, it should be given as a supplementary drug only," said Dr Shah, adding that the bottom line from such findings is steady rise of drug-resistant bacteria which should be addressed through proper use of drugs, their proper duration, and correct diagnosis. Dr RC Damani, internal medicine specialist at KD Hospital, said that compared to the scenario a decade ago, the medical fraternity is now forced to look at alternatives for the AMR typhoid. "Treatment protocols have changed today for antibiotic use. There is better screening also for determining typhoid cases," he said, adding that not all cases of typhoid are of AMR organisms. "The two popular methods to confirm typhoid are blood culture to determine bacteria and sonography to find signs such as swollen lymph nodes. While some start treatment for symptoms, the wrong use of antibiotics can add to the burden of AMR. Typhoid is a very common disease and we have seen a change in form of its duration from five days to seven days and treatment from oral medication to IV in serious cases," said Dr Pragnesh Vachcharajani, secretary of the Federation of Family Physicians' Association of India. Ahmedabad: A recent study has raised alarm bells about the growing resistance of typhoid-causing bacteria to several antibiotics, in some cases up to 90%, potentially complicating treatment options for this common disease. This study by Gujarat Biotechnology Research Centre (GBRC) scientists, along with other organisations, is the latest among several studies in the past decade that flagged the rise of AMR typhoid in Gujarat and in India. Researchers studied isolated Salmonella Typhi or S Typhi, the bacteria responsible for typhoid fever, collected from Ahmedabad and Vadodara against 28 antibiotics used for treatment of typhoid and found several of them showing over 90% resistance. The group also pinpointed genes for third-generation antibiotics for some classes and suggested another class of antibiotics. Typhoid fever, caused by contaminated food or water or poor hygiene, is a common disease for Asia, Africa and Latin America and is marked by fever, fatigue, abdominal pain, rashes and in extreme cases, intestinal bleeding. Symptoms generally last for five to six days and doctors generally use antibiotics for treatment. In Ahmedabad city, monsoons often see 200-odd cases a month. The study, 'Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy' was recently published in the American Society for Microbiology journal Microbiology Spectrum. Its authors include SD Akshay, Heli Upadhyaya and 16 others from GBRC, MS University of Baroda, BJ Medical College, state govt's Commissionerate of Health, and Toprani Labs in Vadodara. 'Determining fluoroquinolones (FQs) and third-generation cephalosporin resistance underscores the urgent need for alternative therapeutic strategiesOur research revealed alarming resistance trends to key antibiotics, such as ceftriaxone, cotrimoxazole, amikacin, ampicillin, cefepime, cefixime, cefotaxime, ciprofloxacin, tetracycline, and gentamicin, limiting effective hospital treatment approaches,' the findings state. The researchers also highlighted the role of specific plasmids that carry resistance genes.'Our findings revealed that combination therapy with β-lactam antibiotics and β-lactam inhibitors (BLI) significantly improved the treatment efficacy against extensively drug resistant (XDR) S. Typhi, contributing to more favourable clinical results and reducing treatment failures,' read the findings, adding that this can effectively manage infections and avoid resistance development. Health experts in Ahmedabad say that the drug-resistant typhoid has been a reality for nearly a decade, in varied frequencies. Dr Urvesh Shah, professor and head of GCS Medical College's microbiology department, said that quinolone, the drug of choice a decade ago, is now getting resistant in more than 50% cases. "While third-generation cephalosporin are a drug of choice, we now get scattered cases of its resistance, which is alarming. While azithromycin retains its sensitivity, it should be given as a supplementary drug only," said Dr Shah, adding that the bottom line from such findings is steady rise of drug-resistant bacteria which should be addressed through proper use of drugs, their proper duration, and correct diagnosis. Dr RC Damani, internal medicine specialist at KD Hospital, said that compared to the scenario a decade ago, the medical fraternity is now forced to look at alternatives for the AMR typhoid. "Treatment protocols have changed today for antibiotic use. There is better screening also for determining typhoid cases," he said, adding that not all cases of typhoid are of AMR organisms. "The two popular methods to confirm typhoid are blood culture to determine bacteria and sonography to find signs such as swollen lymph nodes. While some start treatment for symptoms, the wrong use of antibiotics can add to the burden of AMR. Typhoid is a very common disease and we have seen a change in form of its duration from five days to seven days and treatment from oral medication to IV in serious cases," said Dr Pragnesh Vachcharajani, secretary of the Federation of Family Physicians' Association of India.
